Wednesday, June 10, 2026
🇺🇸 FDA

biotech · Major Depressive Disorder · Schizophrenia · NBIX

NEUROCRINE BIOSCIENCES

NEUROCRINE BIOSCIENCES INC

NEUROCRINE BIOSCIENCES patent portfolio — 111 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
6027 Edgewood Bend Ct, San Diego, California 92130, US HQ
1992 Founded
2,307 Employees
Public company Type
NBIX · NYSE Ticker
Company details
Status
Public
HQ
6027 Edgewood Bend Ct, San Diego, California 92130, US
Founded
1992
Employees
2,307
Programs
79
Drugs
28
Patents
111
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Patents

NEUROCRINE BIOSCIENCES patents

111 pharmaceutical patents indexed for NEUROCRINE BIOSCIENCES. 8 expire within 24 months.

NEUROCRINE BIOSCIENCES has 111 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 8 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

111 patents

Patent portfolio

Page 1 of 3

  1. US 12421193

    GPR52 modulators and methods of use

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12383536

    CRF receptor antagonists and methods of use

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12128033

    Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine

    Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12102637

    Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis

    Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12083227

    Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11730739

    Treatment of congenital adrenal hyperplasia

    Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11718618

    Substituted pyrido[2,1-a]isoquinolines as VMAT2 inhibitors

    Expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11713324

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11654142

    Methods for the administration of certain VMAT2 inhibitors

    Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11459305

    Processes for the preparation of uracil derivatives

    Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11439629

    Methods for the administration of certain VMAT2 inhibitors

    Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11311544

    Treatment of congenital adrenal hyperplasia

    Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11311532

    High dosage valbenazine formulation and compositions, methods, and kits related thereto

    Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11053242

    [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto

    Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11040029

    Methods for the administration of certain VMAT2 inhibitors

    Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11040970

    VMAT2 inhibitor compounds and compositions thereof

    Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11033539

    Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases

    Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11026931

    Methods for the administration of certain VMAT2 inhibitors

    Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11026939

    High dosage valbenazine formulation and compositions, methods, and kits related thereto

    Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11021449

    Substituted triazoles and methods relating thereto

    Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10993941

    Methods for the administration of certain VMAT2 inhibitors

    Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10952997

    Methods for the administration of certain VMAT2 inhibitors

    Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10941159

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10940141

    Methods for the administration of certain VMAT2 inhibitors

    Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10912771

    Methods for the administration of certain VMAT2 inhibitors

    Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10905690

    Treatment of congenital adrenal hyperplasia

    Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10874648

    Methods for the administration of certain VMAT2 inhibitors

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10857137

    Methods for the administration of certain VMAT2 inhibitors

    Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10857148

    Methods for the administration of certain VMAT2 inhibitors

    Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10851103

    Valbenazine salts and polymorphs thereof

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10851104

    Valbenazine salts and polymorphs thereof

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10844058

    Valbenazine salts and polymorphs thereof

    Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10738017

    Substituted triazoles and methods relating thereto

    Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10494347

    Processes for the preparation of uracil derivatives

    Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10336769

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10138214

    Substituted triazoles and methods relating thereto

    Expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10065952

    Valbenazine salts and polymorphs thereof

    Expires Mon Aug 30 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9988382

    [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-A]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto

    Expires Mon May 31 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9868706

    Processes for the preparation of uracil derivatives

    Expires Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9782398

    Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof

    Expires Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9718789

    Substituted triazoles and methods relating thereto

    Expires Mon Jul 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9714246

    [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto

    Expires Mon Jul 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9422310

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Expires Mon Aug 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9382214

    Processes for the preparation of uracil derivatives

    Expires Mon Jun 30 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8952161

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Expires Mon Feb 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8765948

    Processes for the preparation of uracil derivatives

    Expires Mon Jun 26 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8507536

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Expires Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8481731

    Compounds, pharmaceutical composition and methods relating thereto

    Expires Mon Jul 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does NEUROCRINE BIOSCIENCES have?

111 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do NEUROCRINE BIOSCIENCES patents expire?

8 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.